Pål Hasvold

1 ta ish

AstraZeneca (Sweden)

1. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

   Tomas Jernberg, Pål Hasvold, Martin Henriksson +3

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.661364